Hospital

The keynote, Priming Pharmacists for Making an Impact in Oncology Value-Based Care, sets the stage for the entire conference and highlights how pharmacists are critical to the multidisciplinary team in providing value in patient-centered oncology care.

A new study by Prime Therapeutics LLC has shown a sharp increase in the number of drug "super spenders," defined by the researchers as members with pharmacy and medical drug therapy claims of $250,000 or more annually.

A first-in-human trial evaluating the safety, pharmacokinetics, and fecal microbiome effects of a novel DNA polIIIC inhibitor demonstrated the antibacterial’s promise as a potential treatment alternative to vancomycin for the treatment of Clostridioides difficile.

The newly published guidelines answer 16 core questions about the diagnosis and treatment of CAP in adults. The guidelines are more narrow in scope than previous versions and focus primarily on the care of a patient with active pneumonia.

The FDA is continuing to test ranitidine products from multiple manufacturers following the discovery of impurities in low levels in some medicines, including Zantac.

The National Institute on Aging (NIA) has launched 2 new research centers, the Alzheimer Centers for the Discovery of New Medicines, designed to diversify and strengthen the Alzheimer disease drug development pipeline.

Two lawsuits against the FDA have been resolved in a conclusion favorable to Endo International, which argued that vasporessin should be excluded from the agency’s compounding list.

Oprah Winfrey’s message is clear: the flu and pneumonia vaccines are important.

Johnson & Johnson and its Janssen Pharmaceutical Cos unit have agreed to a more than $10 million settlement, rather than allowing the matter go to federal trial.

Fulvestrant injection treats certain types of breast cancer in post-menopausal women who were not previously treated with endocrine therapy and as a combination for advanced or metastatic breast cancer.

Ivosidenib improved progression-free survival with a promising trend toward improved overall survival in patients with IDH1-mutated cholangiocarcinoma.

Apalutamide (Erleada) showed an overall survival benefit in patients with non-metastatic castration-resistant prostate cancer.

A session at the ESMO Congress 2019 highlighted potential prevention and treatment strategies for life-threatening immunotherapy toxicities in patients with cancer.

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen, discussed the increasing value of precision medicine in oncology and what will be needed to facilitate the use of precision medicine as more agents become available.

Officials from the FDA have approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s canagliflozin (Invokana) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 Diabetes and chronic kidney disease (CKD).

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen explained the challenges in identifying and treating TRK fusion cancer in patients.

New data confirm high activity of larotrectinib in pediatric and adult patients with TRK fusion cancer.

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, professor of oncology at the University of Copenhagen, discussed the newly-released clinical data highlighting new overall survival and progression-free survival results for larotrectinib (Vitrakvi, Bayer) in tropomyosin receptor kinase (TRK) fusion cancer.

Treatment with a CDK4/6 inhibitor plus fulvestrant found to improve overall survival in women with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer.

The addition of the immunotherapy pembrolizumab (Keytruda) to standard presurgical chemotherapy improved pathological complete response (pCR) rates for patients with triple-negative breast cancer (TNBC).

A pharmacist and nurse led non-medical prescribing clinic that was focused on side effect management and survivorship support for patients with melanoma helped to improve common every-day pressure seen in a medical day unit and improved overall patient experience.

At the ESMO Congress 2019, Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, talked about how ovarian cancer treatment has evolved over the years.

The PRIMA study evaluated the efficacy and safety of niraparib therapy after response to platinum-based chemotherapy in patients with newly-diagnosed ovarian cancer.

At the ESMO Congress 2019, Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, discussed the role of oncology pharmacists in managing the treatment of patients with ovarian cancer.

New data presented at the ESMO Congress 2019 showed that a 2-drug immunotherapy combination improved overall survival in patients with advanced non-small cell lung cancer.

Late-breaking data from the ESMO Congress 2019 demonstrate osimertinib’s superiority to older generation EGFR tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer.

At ESMO Congress 2019, Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, discussed the latest practice-changing clinical data results involving PARP inhibitor therapy in ovarian cancer.

Five-year overall survival rates in patients with melanoma were 52% for nivolumab plus ipilimumab, 44% for nivolumab, and 26% for ipilimumab.  

Daratumumab was approved based on results from part one of the Phase III CASSIOPEIA study.

The European Society for Medical Oncology (ESMO) Congress 2019 will be taking place September 27 to October 1 in Barcelona, Spain, and Pharmacy Times® and Specialty Pharmacy Times® will be on location delivering coverage.